Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03605342 · ClinicalTrials.gov registry record · Phase 2
Optimal Treatment of Veterans With PTSD and Comorbid OUD
A Phase 2 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT03605342: Clinical Trial Phase 2 study, sponsored by VA Office of Research and Development.
NCT03605342 is a Phase 2 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03605342, a Phase 2 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The objective of this study is to test a standard psychotherapy for PTSD in Veterans who also suffer from Opiate Use Disorder (OUD). Specifically, this study will test whether Cognitive Processing Therapy (CPT)-C is more effective in treating PTSD, compared to a control group (Individual Drug Counseling (IDC); which approximates treatment as usual), among Veterans with PTSD and comorbid OUD who are maintained on buprenorphine. The study has three phases. In Phase I: induction to buprenorphine/naloxone (BUP/NLX) maintenance. Phase II: treatment. During this phase participants will be randomly assigned to CPT-C or IDC for 12 weeks. They will be seen weekly for psychotherapy and also regularly (weekly, then biweekly, then monthly) for buprenorphine management, symptom evaluation, and medication refill. After completing treatment participants will be referred to a buprenorphine clinic for ongoing care. Phase III: follow-up. Approximately 160 male and female Veterans (18-65 years old) with PTSD and comorbid opiate use disorder (OUD) will be enrolled in this study. Recruitment will be through VA clinics, word-of-mouth, referrals from area programs and by advertisement. Veterans who are interested will complete a brief pre-screening and detailed in-person screening. After completing the screening process, all eligible participants will be started on buprenorphine maintenance and once withdrawal symptoms are stabilized, participants will be randomly assigned to 1 of 2 conditions (CPT-C or IDC) for 12 weeks. Veterans who are already on BUP/NLX will be allowed to participate and will start at Phase II of the study, after completing the screening.
Interventions
- DRUG Buprenorphine
- BEHAVIORAL Cognitive Processing Therapy (CPT)
- BEHAVIORAL Individual Drug Counseling (IDC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03605342
The ClinicalTrials.gov registry entry for NCT03605342 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Buprenorphine is the first listed.
NCT03605342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03605342 about?
NCT03605342 is a clinical study titled "Optimal Treatment of Veterans With PTSD and Comorbid OUD". The objective of this study is to test a standard psychotherapy for PTSD in Veterans who also suffer from Opiate Use Disorder (OUD). Specifically, this study will test whether Cognitive Processing Therapy (CPT)-C is more effective in treating PTSD, compared to a control group (Individual Drug Counse...
What is the current status of trial NCT03605342?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2018-10-01. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT03605342?
The interventions under investigation include: Buprenorphine (DRUG), Cognitive Processing Therapy (CPT) (BEHAVIORAL), Individual Drug Counseling (IDC) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03605342?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.